A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Retifanlimab-Dlwr (ZYNYZ)

Retifanlimab-Dlwr helps the immune system fight cancer by blocking PD-1 immune checkpoints.

First FDA approval2023-03-22
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Retifanlimab-Dlwr used for?

Retifanlimab-Dlwr helps the immune system fight cancer by blocking PD-1 immune checkpoints.

Is there a generic for Retifanlimab-Dlwr?

No. Retifanlimab-Dlwr is brand-only with no generic equivalents currently in market.

How much does my plan pay for Retifanlimab-Dlwr?

NADAC pricing data not currently available for this drug.

Is Retifanlimab-Dlwr on the FDA shortage list?

No. Retifanlimab-Dlwr is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Programmed Death Receptor-1 Blocking Antibody6 alternatives in D1
01
Atezolizumab
Brand: TECENTRIQ
Lowest NADAC
0Generic mfrs
$37.8MCY24 Part D spend
Compare →
02
Atezolizumab and Hyaluronidase-Tqjs
Brand: Tecentriq Hybreza
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Dostarlimab
Brand: Jemperli
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
04
Nivolumab
Brand: OPDIVO
Lowest NADAC
0Generic mfrs
$80.7MCY24 Part D spend
Compare →
05
Nivolumab and Hyaluronidase-Nvhy
Brand: OPDIVO QVANTIG
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
06
Nivolumab and Relatlimab-Rmbw
Brand: OPDUALAG
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.